Breakthrough Acceleration: Sickle Cell Anemia Testing & Screening Market to Hit USD 1125.33 million by 2032 at 12.30% CAGR

Rising Need for Early Diagnosis Fuels Global Growth Momentum

The sickle cell anemia testing & screening market, valued at USD 440.65 million in 2024, is forecast to reach USD 1125.33 million by 2032 at a CAGR of 12.30%. The sharp rise in sickle cell disease incidence across sub-Saharan Africa, India, the Middle East, and parts of the U.S. is heightening demand for early, accurate, and cost-efficient testing solutions. More than 300,000 babies are born annually with sickle cell disease, a number expected to hit 400,000 by 2050 according to WHO. This rising clinical burden is compelling governments and international health organizations to expand newborn screening programs and strengthen public awareness initiatives.

The U.S. remains a dominant regional contributor, reaching an estimated USD 367.87 million by 2032 with strong federal screening mandates and a high prevalence within African-American communities. As newborn screening policies expand globally, molecular diagnostics and point-of-care tools are being adopted as essential components of preventive healthcare systems.

Track the Latest Market Developments: Request a Sample Report: https://www.snsinsider.com/sample-request/8190

Government-Led Screening Programs and Global NGO Participation Strengthen Market Expansion

One of the central forces shaping the sickle cell anemia testing & screening market growth is the large-scale deployment of screening programs by health ministries, public health agencies, and global NGOs. The CDC, WHO, NIH, and UNICEF are actively standardizing newborn testing guidelines and facilitating training support in high-burden countries. These efforts have significantly widened access to early diagnosis, particularly in regions lacking specialist medical facilities.

Technology innovation is further accelerating adoption. Recent developments such as low-cost microfluidic chip testing have reduced infrastructure dependency, enabling rapid diagnoses even in remote territories without trained laboratory technicians. In 2024, BioMedomics introduced its next-generation Sickle SCAN test, delivering results in under five minutes and now widely deployed across Africa and Southeast Asia, supporting mass-screening initiatives.

Challenges in Awareness and Stigma Continue to Limit Screening Penetration in Rural and Underserved Markets

Despite strong progress, limited public understanding of sickle cell disease remains a major barrier in several high-prevalence regions. Cultural stigma around genetic disorders and misconceptions about disease inheritance lead to poor engagement with testing programs. Research published in BMC Public Health showed that in certain African nations, fewer than 20% of surveyed mothers were aware of sickle cell disease, and less than 10% understood its hereditary nature. This reduces uptake of newborn screening and inhibits follow-up diagnostic compliance.

Infrastructure shortages, particularly in rural populations, further slow testing adoption. Although governments are working to strengthen healthcare access, continued investment in awareness campaigns and community education is necessary to overcome the knowledge gap and expand screening coverage.

Hemoglobin Electrophoresis Retains Dominance as the Gold-Standard Diagnostic Method Worldwide

By test type, hemoglobin electrophoresis accounted for 31.5% of the global sickle cell anemia testing & screening market in 2024. Its accuracy, specificity, and ability to distinctly differentiate between sickle cell disease and sickle cell trait make it a clinically preferred confirmatory test. Integrated into most newborn screening protocols, it remains a critical laboratory tool for early detection.

Meanwhile, point-of-care tests are projected to record the highest CAGR as healthcare efforts prioritize rapid community-level diagnostics. Portable devices offering low-cost, instant results are gaining widespread adoption among NGOs and public health missions across Africa, Asia, and Latin America.

Molecular Testing Leads Technology Adoption as Precision Diagnostics Gain Global Momentum

The molecular testing segment dominated the sickle cell anemia testing & screening market in 2024, supported by PCR, DNA sequencing, and advanced genetic platforms that allow the earliest and most precise identification of hemoglobin mutations. As developing economies expand their diagnostic infrastructure, molecular tools are transitioning from specialized labs into mainstream public health settings.

This segment is also expected to grow the fastest due to declining costs of genetic testing, increased prenatal diagnostics, and rising global emphasis on preventing hereditary disorders through early screening.

Newborn Population Remains the Largest Screening Group as Governments Prioritize Life-Saving Early Detection

Newborn screening captured 43.15% of the market in 2024, cementing its position as the highest contributing age group. Early detection significantly reduces complications, supports timely interventions, and improves survival outcomes. Countries with high birth rates and growing healthcare programs, particularly in Sub-Saharan Africa and India, are increasingly mandating universal newborn testing.

Other age groups—from school-aged children to older adults—are set to grow rapidly due to late diagnoses, rising public health check-ups, and broader insurance coverage.

Government Laboratories Maintain Market Leadership While Private Labs Record Fastest Growth

In 2024, government laboratories held 40.11% of the market share due to extensive population-level screening campaigns and subsidized diagnostics. These public health-driven efforts are crucial in high-prevalence, low-income regions.

Private diagnostic laboratories, however, are forecast to grow at the highest CAGR as awareness rises, disposable incomes improve, and molecular testing becomes more accessible. Partnerships between private labs and telemedicine platforms are expanding urban and semi-urban screening access.

Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report: https://www.snsinsider.com/reports/sickle-cell-anemia-testing-and-screening-market-8190

North America Leads with Strong Screening Mandates; Asia Pacific Emerges as the Fastest-Growing Region

North America represented 43.60% of the market in 2024 on account of robust healthcare systems, newborn screening legislation, and increasing adoption of molecular tools. In contrast, Asia Pacific is expanding at 13.43% CAGR due to rising awareness, larger birth cohorts, and substantial government investment in hemoglobinopathy screening.

Europe continues to strengthen its market presence through newborn screening expansions and improved genetic testing access. Meanwhile, Latin America and the MEA region experience moderate but steady progress driven by gradual healthcare advancements and growing involvement of international health partners.

Recent Advancements Strengthen Competitive Landscape

Key companies operating in the sickle cell anemia testing & screening market include Bio-Rad Laboratories, Thermo Fisher Scientific, Abbott, PerkinElmer, Natera, BioMedomics, Danaher Corporation, Siemens Healthineers, Roche Diagnostics, Hemex Health, Cepheid, and others.

Recent innovations such as Bio-Rad’s enhanced VARIANT System for newborn genetic screening and Thermo Fisher’s 2024 launch of an array-based extended blood typing solution are redefining standards in diagnostic accuracy and throughput.

Other Trending Reports

Small Molecule API Market

Human Growth Hormone Market

Clinical Trial Investigative Site Network Market

Polyclonal Antibodies Market